Veru Inc. (VERU) News

Veru Inc. (VERU): $7.36

-1.43 (-16.33%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter VERU News Items

VERU News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

VERU News Highlights

  • For VERU, its 30 day story count is now at 4.
  • Over the past 22 days, the trend for VERU's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about VERU are STAR, FSTX and AMP.

Latest VERU News From Around the Web

Below are the latest news stories about Veru Inc that investors may wish to consider to help them evaluate VERU as an investment opportunity.

10 “Strong Buy” Healthcare Stocks With Over 100% Upside Potential According to Top Analysts

With so many people giving investment advice online, it can seem that you only need an email address to become a financial influencer. Meanwhile, financial analysts with a proven track record carefully research companies and produce detailed reports with their recommendations and reasoning behind them. The TipRanks stock screener enables investors to easily search for stocks according to different criteria. These include the analyst consensus and price targets of the top-performing Wall Street analysts. We used it to search for stocks with the highest upside potential as we head towards May 2021.

Varda Bachrach on TipRanks | April 27, 2021

2 “Strong Buy” Stocks Around $10 With Triple-Digit Upside Potential

The S&P 500 rose to another record high on Friday, and at least one strategist believes we’re at the start of a new bull market. Writing from LPL Financial, chief market strategist Ryan Detrick noted several market-historical points that indicate sustained gains are in the offing. Key among his points are the first quarter returns and the breadth of the current stock rally. On returns, Detrick highlights that the S&P 500 gained nearly 6% in Q1 – and that the 6% level has been an accurate indicator for near-term trends.

Michael Marcus on TipRanks | April 16, 2021

Are Options Traders Betting on a Big Move in Veru (VERU) Stock?

Investors need to pay close attention to Veru (VERU) stock based on the movements in the options market lately.

Yahoo | April 5, 2021

Looking Into Veru's Return On Capital Employed

Veru (NASDAQ:VERU) showed a loss in earnings since Q4, totaling $777.00 thousand. Sales, on the other hand, increased by 24.41% to $14.62 million during Q1. Veru collected $11.75 million in revenue during Q4, but reported earnings showed a $11.27 million loss. Why ROCE Is Significant Changes in earnings and sales indicate shifts in Veru's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q1, Veru posted an ROCE of 0.02%. It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affec...

Yahoo | March 18, 2021

Analyzing Veru (NASDAQ:VERU) & Atossa Therapeutics (NASDAQ:ATOS)

Atossa Therapeutics (NASDAQ:ATOS) and Veru (NASDAQ:VERU) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends. Volatility & Risk Atossa Therapeutics has a beta of 2.34, suggesting that its share price is […]

Modern Readers | March 11, 2021

Veru to Present at the Oppenheimer 31st Annual Healthcare Conference

MIAMI, March 09, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the Company will present at the Oppenheimer 31st Annual Healthcare Conference. The presentation will be available through the Conference on Tuesday, March 16th at 3:10 p.m. ET. The presentation will also be available at https://verupharma.com/investors. The webcast will be archived and accessible on the web site for at least 90 days. About Veru Inc.Veru Inc. is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer. The Veru prostate cancer pipeline includes VERU-111, VERU-100, and Zuclomip...

Yahoo | March 9, 2021

Veru Hires Advisor To Explore Alternatives For Female Health Business

Veru Inc (NASDAQ: VERU) has engaged Morgan Stanley as a financial advisor to pursue strategic alternatives for its legacy Female Healthcare Business. "Furthermore, with the potential for five registration clinical trials in the calendar year 2021, four for oncology indications and one for COVID-19 it is clear that Veru has transformed itself into a premium, late-stage, clinical biopharmaceutical company, so the strategic fit with the FHC Business is not as strong as it once was," said Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer. For the fiscal year 2020, the business reported net revenues of $41 million and gross profit of $29 million. Its commercial product is the FC2 Female Condom/ FC2 Internal Condom, the only FDA-approved female condom. Price Action: VER...

Yahoo | March 8, 2021

Veru mulls selling female health business

Shares of Veru Inc. gained 6.5% in trading on Monday after the company said it is considering selling its female condom product. Veru hired Morgan Stanley & Co. as its financial advisor, saying the female condom business was no longer a strategic fit for the company now that it is advancing oncology and COVID-19 products through clinical trials. "It is clear that Veru has transformed itself into a premium, late-stage, clinical biopharmaceutical company, so the strategic fit with the [female health company] business is not as strong as it once was," Dr. Mitchell Steiner, Veru's president and CEO, said in a news release. The female condom business generated $41 million in net revenue in 2020, though the sexual health product, which is the only one of its kind, makes up less than 2% of tot...

Yahoo | March 8, 2021

Veru Exploring Strategic Alternatives for its Legacy Female Health Business

MIAMI, March 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer, today announced that it has engaged Morgan Stanley & Co. LLC as a financial advisor to assist the Company and its management in pursuing strategic alternatives regarding its legacy FC2 Female Condom® / FC2 Internal Condom business (FHC Business). “With the last two consecutive quarters for our FHC Business having set all-time historical records in terms of net revenues and gross profit, and with the last three-year compound annual growth rates for the FHC Business’ net revenues and gross profit being 60% and 83%, respectively, we think this is an ideal time to consider strategic alter...

Yahoo | March 8, 2021

Veru to Participate in Fireside Chat at the H.C. Wainwright Global Life Sciences Conference

MIAMI, March 02, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the Company will participate in a fireside chat at the H.C. Wainwright Global Life Sciences Conference. The fireside chat will be available on-demand through the Conference on March 9th, 2021 starting at 7 a.m. ET. The fireside chat will also be available at https://verupharma.com/investors. The webcast will be archived and accessible on the web site for at least 90 days. About Veru Inc.Veru Inc. is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer. The Veru prostate cancer pipeline in...

Yahoo Finance | March 2, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6882 seconds.